Abstract
We were unable to confirm the finding of Crowle that TESA possesses the attribute of immunogenicity and absence of allergenicity which are desired in a non-living antituberculosis vaccine. This disagreement could be a function of the particular lot of TESA examined and/or differences in the animal test systems used for the assay of protective potency. The relative contribution of these two possibilities could be determined by the simultaneous assay of a potent TESA product in different laboratories using different animal models.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
